Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001171 · ClinicalTrials.gov registry record
Evaluation of Factors in Human Brain Tumors
A clinical trial, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 800
- Enrollment target
NCT00001171 is a clinical trial that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 800 participants.
The verdict
NCT00001171 has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
Study Summary
Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy). Patients that receive additional therapy can increase life expectancy to 50 weeks. The statistics on the life expectancy and survival have increased efforts among researchers to develop new treatments for primary malignant brain tumors. This research project involves the growth and study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective treatments for them.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 1979-07 |
| Est. Completion | 2005-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001171
The ClinicalTrials.gov registry entry for NCT00001171 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001171 about?
NCT00001171 is a clinical study titled "Evaluation of Factors in Human Brain Tumors". Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy). Patients that receive additional therapy can increase life expectancy to 50 weeks. The sta...
What is the current status of trial NCT00001171?
This trial is currently completed. The enrollment target is 800 participants. The study started on 1979-07. Estimated completion is 2005-09.
Who is sponsoring clinical trial NCT00001171?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.